Physician profile
John Evanoff
NPI 1093714503
$10,156.32
in general payments reported to CMS, 2019-2025
34 companies · $2,049 in 2025
The $2,049 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,193 · 2020: $1,601 · 2021: $1,695 · 2022: $1,253 · 2023: $587 · 2024: $1,778 · 2025: $2,049.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,414.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,414.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,577.61 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $1,192.57 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $1,045.28 | 2019-2025 | |
| Abbvie INC. | $829.31 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $661.88 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $579.37 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $483.00 | 2019-2025 | Otezla, Repatha, Otezla |
| Janssen Pharmaceuticals, INC | $418.10 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $388.19 | 2023-2025 | Rexulti |
| Axsome Therapeutics, INC. | $292.34 | 2024-2025 | Auvelity, Symbravo |
| Merck Sharp & Dohme LLC | $284.06 | 2019-2023 | Steglatro |
| Kowa Pharmaceuticals America, INC. | $257.54 | 2019-2024 | Zoryve, Livalo |
| Novartis Pharmaceuticals Corporation | $239.99 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $194.38 | 2019-2024 | Gattex |
| Allergan, INC. | $191.86 | 2019-2020 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $180.42 | 2023-2025 | Cologuard Collection Kit |
| Amarin Pharma, INC. | $171.86 | 2019-2021 | |
| Glaxosmithkline, LLC. | $163.58 | 2021-2025 | Trelegy Ellipta, Arexvy |
| Lundbeck LLC | $143.52 | 2024-2025 | Rexulti |
| Abbott Laboratories | $142.41 | 2023-2025 | Freestyle Libre 3 |
| Biohaven Pharmaceuticals, INC. | $132.91 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $113.14 | 2021-2025 | |
| Phathom Pharmaceuticals, INC. | $94.60 | 2024-2025 | Voquezna |
| Biohaven Pharmaceutical Holding Company Ltd. | $86.27 | 2022 | |
| Biogen, INC. | $55.62 | 2021 | |
| Genentech USA, INC. | $48.87 | 2020-2021 | |
| Corcept Therapeutics | $40.27 | 2019 | |
| Paratek Pharmaceuticals, INC. | $37.95 | 2024-2025 | Nuzyra |
| Dexcom, INC. | $25.01 | 2024 | Dexcom G6 Transmitter |
| Astellas Pharma US INC | $20.47 | 2024 | Veozah |
| Nestle Healthcare Nutrition INC. | $20.08 | 2021 | |
| Almatica Pharma LLC | $18.30 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $13.41 | 2023 | Camzyos |
| Sanofi-Aventis U.S. LLC | $12.15 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Evanoff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.